PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER

米诺环素在癌症患者中的 I 期试验

• 批准号: 6291094
• 负责人: Michael Gordon
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291094
• 关键词: clinical research; clinical trial phase I; enzyme inhibitors; human subject; human therapy evaluation; metalloendopeptidases; metastasis; neoplasm /cancer chemotherapy; tetracyclines

The purpose of this research study is to determine the side effects of increasing doses of minocycline and to determine the maximum dose of minocycline that patients can tolerate. This study will also assess how long it takes for minocycline to leave the patients body. Minocycline is an antibiotic which is approved by the Food and Drug Administration for the treatment of certain infections. New research has revealed that it has the ability to inhibit the activity of certain enzymes in cancer cells which are important in allowing tumor cells to grow and spread. These results suggest that minocycline may help the patients body to stop or prevent the further growth of the patients cancer.

本研究的目的是确定增加米诺环素剂量的副作用，并确定患者可以耐受的米诺环素最大剂量。 这项研究还将评估米诺环素离开患者身体需要多长时间。 米诺环素是一种抗生素，经美国食品和药物管理局批准用于治疗某些感染。 新的研究表明，它能够抑制癌细胞中某些酶的活性，这些酶对于肿瘤细胞的生长和扩散非常重要。 这些结果表明米诺环素可以帮助患者的身体阻止或防止患者癌症的进一步生长。